World

Anvisa approves import of experimental drug for Lito Sousa

Anvisa has authorized the import of an experimental drug to treat Lito Sousa, diagnosed with Creutzfeldt-Jakob disease.

4 September 2026Tagblick Newsdesk

AI-generatedWritten by an AI system, editorially responsible — how we work

Archive photo: Anvisa approves import of experimental drug for Lito Sousa — Archive photoPhoto: Pract Neurol · Wikimedia Commons · CC BY 4.0

The National Health Surveillance Agency (Anvisa) granted approval on Friday (4) for the import of an experimental drug to treat influencer Lito Sousa. The drug, designated ALN-6457, is still in testing phases and does not have commercial registration in Brazil.

According to reports, the authorization was granted exceptionally, as the product does not have a legal representative in the country. This process followed a procedure outside the standard flow for drug imports.

Lito Sousa was recently diagnosed with Creutzfeldt-Jakob disease (CJD), a rare and incurable neurodegenerative condition. The influencer's health status prompted the search for alternative treatments.

Anvisa emphasized the importance of ensuring access to new treatments, even those still in experimental phases, for cases deemed critical. This specific case illustrates measures that can be taken when a drug is not available in the Brazilian market.

Furthermore, the authorization represents an exception in terms of health regulation, as it involves a product that is not commercially available and is in the early stages of development.

This item was written by an AI system on the basis of the headlines and short teasers of the independently operating newsrooms named below. We disclose this under Art. 50(4), second subparagraph, of Regulation (EU) 2024/1689 (AI Act). Before publication we check origin and verifiability — anything that appears in only one place is not published — as well as language, substance and legally sensitive content. No separate substantive review of each individual item by a natural person takes place; we therefore do not rely on the exemption in Art. 50(4), second subparagraph, of the AI Act. Editorial responsibility for this publication rests with the person named in the imprint (§ 18 Abs. 2 MStV). Please report errors to [email protected] — we will correct or remove the item. Full reports are available from the sources listed.